10-Q: AN2 Therapeutics Reports Q2 2026 Results, Advances Pipeline

AN2 Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in research and development, progress in clinical trials for epetraborole and AN2-502998, and a strong cash position.

Summary

• AN2 Therapeutics reported a net loss of $8.2 million for the three months ended June 30, 2026, compared to a $6.5 million loss in the same period of 2025. For the six months ended June 30, 2026, the net loss was $18.2 million, an increase from $17.1 million in the prior year.
• Research and development expenses increased by 88% to $6.0 million for the three months ended June 30, 2026, driven by higher CMC, consulting, preclinical, and clinical trial expenses.
• General and administrative expenses decreased by 28% to $2.9 million for the three months ended June 30, 2026, primarily due to lower professional services and personnel-related costs.
• The company had $79.9 million in cash, cash equivalents, and investments as of June 30, 2026, which management believes is sufficient to fund operations for at least 12 months.
• AN2 Therapeutics is expanding its Phase 2 study of epetraborole for polycythemia vera (PV) with an IND filing expected in Q3 2026 and enrollment anticipated in Q4 2026.
• The company is also advancing AN2-502998 for Chagas disease, with a Phase 2 proof-of-concept study expected to initiate in late 2026, following positive non-human primate and Phase 1 study results.
• Development of epetraborole for M. abscessus lung disease is ongoing via an investigator-initiated trial, with topline results expected in late 2027.
• The company has discontinued further development of epetraborole for treatment-refractory MAC lung disease due to the Phase 3 portion of the EBO-301 study not meeting its primary endpoint.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious outlook due to continued net losses and reliance on future financing, despite progress in clinical development.

Positives

• Secured $37.2 million in net proceeds from the 2026 Private Placement in March 2026.
• Raised $1.4 million in net proceeds from ATM Offerings in the first six months of 2026.
• Positive results from non-human primate and Phase 1 studies for AN2-502998 in Chagas disease.
• Expanded development plans for epetraborole in polycythemia vera (PV), with a pre-IND meeting held with the FDA.
• Cash, cash equivalents, and investments totaled $79.9 million as of June 30, 2026, providing at least 12 months of operating runway.
• Received $0.2 million in funding under the NIAID contract during the six months ended June 30, 2026.
• Received $0.8 million in funding under the Gates Foundation grant during the six months ended June 30, 2026.
• Stock-based compensation expense decreased significantly compared to the prior year.

Negatives

• Reported a net loss of $8.2 million for Q2 2026 and $18.2 million for the first six months of 2026.
• Research and development expenses increased significantly by 88% year-over-year for Q2 2026.
• Discontinued development of epetraborole for MAC lung disease due to failure to meet primary endpoints in Phase 3 study.
• Accumulated deficit reached $259.2 million as of June 30, 2026.
• The company has no products approved for sale and has not generated revenue.
• Reliance on future financing to fund operations and development activities.
• Identified material weaknesses in internal control over financial reporting.
• Interest income decreased by 24% for the six months ended June 30, 2026, due to lower balances and rates.

Risks

• The company has a limited operating history and no products approved for commercial sale, with significant expected losses in the coming years.
• Clinical trials for product candidates are subject to inherent risks, and clinical proof of concept has not yet been established for any of its programs.
• Substantial additional funding is required, and failure to raise capital could lead to delays or cessation of development programs.
• Failure to obtain regulatory approval for product candidates will prevent commercialization and revenue generation.
• Reliance on third-party service providers for preclinical and clinical trial conduct, which could lead to delays if they fail to meet contractual duties.
• Competition from other biopharmaceutical companies, including larger entities with greater resources.
• The company has identified material weaknesses in its internal control over financial reporting, which could affect its ability to accurately report financial condition.
• The company's success is dependent on retaining key personnel and attracting qualified talent in a competitive market.

Future Outlook

The company believes its current cash, cash equivalents, and investments of $79.9 million as of June 30, 2026, will be sufficient to fund its operating plan through at least twelve months from the issuance date of the financial statements. However, substantial additional funding will be required to continue operations and advance product candidates through development and potential commercialization.

Management Comments

• We believe that our available cash will be sufficient to fund our planned operations under our current operating plan through at least twelve months following the date of this Form 10-Q.
• We expect that our operating expenses will increase significantly as we advance our current and future product candidates through preclinical, nonclinical, and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization.

Industry Context

StockSavvy.ai notes that AN2 Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector. The company's focus on novel small molecule therapeutics derived from its boron chemistry platform aligns with industry trends of seeking differentiated approaches to address unmet medical needs. However, the significant R&D expenses and continued net losses are typical for clinical-stage biopharma companies, highlighting the inherent risks and the critical need for successful clinical outcomes and subsequent financing.

Comparison to Industry Standards

• Biopharmaceutical companies at a similar clinical stage often incur substantial R&D expenses and report net losses, as demonstrated by AN2 Therapeutics' financial results.
• The cash burn rate of approximately $19.1 million for the first six months of 2026 is within the range expected for companies advancing multiple clinical programs.
• The company's reliance on equity financing, including private placements and ATM offerings, is a common strategy for clinical-stage biopharma companies to fund operations.
• The decision to discontinue a program due to failure to meet clinical endpoints, as seen with epetraborole for MAC lung disease, is a frequent occurrence in drug development.

Legal Proceedings

• The company was not subject to any material legal proceedings as of June 30, 2026, and is not currently a party to any legal proceeding that is expected to have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• Approximately $30.0 million of the $40.0 million gross proceeds raised in the 2026 Private Placement were received from significant stockholders.

Stakeholder Impact

• Shareholders: Continued net losses and reliance on future financing may impact stock value. Progress in clinical trials could positively influence future share price.
• Employees: The company's financial performance and development progress are critical for job security and potential stock option value.
• Creditors: Not directly impacted as the company is primarily equity-financed, but continued losses could affect future creditworthiness.
• Partners/Collaborators: Progress in clinical trials and successful funding rounds are important for continued collaboration and potential milestone payments.

Next Steps

• Advance epetraborole into a Phase 2 proof-of-concept clinical study in adults with polycythemia vera (PV).
• File an IND for the PV Phase 2 study in the third quarter of 2026.
• Commence Phase 2 enrollment for PV in the fourth quarter of 2026.
• Initiate a Phase 2 proof-of-concept study of AN2-502998 in chronic Chagas disease in late 2026.
• Advance a second development candidate (ENPP1) for solid tumors by the end of 2026.
• Continue discussions with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis.
• Report topline results from the M. abscessus lung disease investigator-initiated trial in late 2027.

Key Dates

Recommendation

AN2 Therapeutics is a clinical-stage biopharmaceutical company with promising pipeline candidates but faces significant risks associated with drug development, regulatory approval, and the need for substantial future financing. While the company has made progress in its clinical programs and secured funding, the continued net losses and the discontinuation of one development program warrant a cautious approach. Investors should monitor clinical trial results and future financing activities closely. A 'hold' recommendation reflects the balance between potential upside from successful drug development and the inherent risks in the sector.

Keywords

biopharmaceutical, clinical-stage, drug development, epetraborole, AN2-502998, Chagas disease, polycythemia vera, M. abscessus lung disease